BioSpace News Archive

Utah Medical Products, Inc. announces that its Board of Directors, acting by unanimous written consent, terminated the Company’s Shareholder Rights Agreement, sometimes referred to as a “poison pill.” The Rights Agreement with a ten year life was originally approved by a vote of all shareholders at the 1994 Annual Meeting, and then was extended in 2004 and again in 2014 by the board without a shareholder vote.

The U.S. Food and Drug Administration has authorized marketing of the Hominis Surgical System, a new robotically-assisted surgical device (RASD) that can help facilitate transvaginal hysterectomy in certain patients.

Innova Medical Group, Inc., the world’s largest manufacturer of rapid antigen test kits and leader in COVID-19 testing solutions globally, announced today the appointment of Sean Rogers as Chairman of Innova Medical Group, and Todd Malan, M.D., as Innova’s Chief Medical Officer.

Milliken & Company, a global diversified manufacturer with more than a century and a half of materials science expertise, has formally acquired Zebra-chem GmbH, a global chemicals company known for its peroxide and blowing agent masterbatches.

OmniTier announced that its CompStor® family now supports mitochondrial analysis in both its secondary and tertiary analysis appliances.

Memic, a medical device company dedicated to transforming robot-assisted surgery with its proprietary technology, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization of its Hominis® robot-assisted surgical platform for use in single site, natural orifice laparoscopic-assisted transvaginal

The board of directors of Targovax ASA has resolved to increase the share capital of the Company following the completion of an exercise period for vested share options under the Company’s long-term incentive program for employees.

Each unit will consist of one common share and one transferable common share purchase warrant of the Company, with each whole warrant exercisable for a period of 12 months from the date of closing at a price of $0.27 per share.

By 1999 Dr. Konstantin ‘Gus’ Kousoulas was a tenured professor and consultant. While he wasn’t extremely wealthy, he considered himself successful and satisfied with where life was going.

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate at the following investor conferences: